aTyr Pharma
ATYR
29 hedge funds and large institutions have $33.8M invested in aTyr Pharma in 2021 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 11 increasing their positions, 5 reducing their positions, and 3 closing their positions.
700% more call options, than puts
Call options by funds: $96K | Put options by funds: $12K
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
120% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 5
28% more capital invested
Capital invested by funds: $26.3M → $33.8M (+$7.45M)
16% more funds holding
Funds holding: 25 → 29 (+4)
6.14% more ownership
Funds ownership: 36.92% → 43.05% (+6.1%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.28M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.24M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$667K |
| 4 |
Two Sigma Advisers
New York
|
+$451K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$389K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$280K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$255K |
| 3 |
BlackRock
New York
|
-$121K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$64.2K |
| 5 |
SWM
Spire Wealth Management
Mclean,
Virginia
|
-$63K |
ATYR Hedge Fund Activity: Q2 2021 in Review
29 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q2 2021, worth a combined $33.8M — up 28% from $26.3M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ATYR positions and 3 closed out — a net gain of 4 holders — while 11 added to existing stakes and 5 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.28M. The largest seller was Renaissance Technologies, cutting an estimated $280K.
- 29 institutional investors held aTyr Pharma (ATYR) as of Q2 2021, up from 25 in Q1 2021.
- Funds reported $33.8M of aTyr Pharma stock for Q2 2021, up 28% quarter-over-quarter.
- 7 funds opened new aTyr Pharma positions in Q2 2021 and 3 closed out, a net change of +4 holders.
- The largest aTyr Pharma buyer in Q2 2021 was Vanguard Group, an estimated $1.28M added.
- The largest aTyr Pharma seller in Q2 2021 was Renaissance Technologies, an estimated $280K sold.
Based on aggregated 13F filings for Q2 2021.